These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26463904)

  • 41. Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally.
    Wong A; Macleod D; Robinson J; Koutsogiannis Z; Graudins A; Greene SL
    Clin Toxicol (Phila); 2015; 53(8):815-8. PubMed ID: 26109423
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.
    Mannelli P; Patkar AA; Peindl K; Murray HW; Wu LT; Hubbard R
    J Clin Psychopharmacol; 2007 Oct; 27(5):468-74. PubMed ID: 17873678
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mr R: a case study of withdrawal.
    Dennison SJ
    Behav Med; 1992; 18(3):139-40. PubMed ID: 1330103
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The opioid receptor antagonist nalmefene reduces responding maintained by ethanol presentation: preclinical studies in ethanol-preferring and outbred Wistar rats.
    June HL; Grey C; Warren-Reese C; Durr LF; Ricks-Cord A; Johnson A; McCane S; Williams LS; Mason D; Cummings R; Lawrence A
    Alcohol Clin Exp Res; 1998 Dec; 22(9):2174-85. PubMed ID: 9884166
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Discrimination learning in oxycodone-treated nonhuman primates.
    Withey SL; Doyle RJ; Porter EN; Bergman J; Kangas BD
    Drug Alcohol Depend; 2020 Feb; 207():107778. PubMed ID: 31816487
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Nalmefene: a novel pharmacotherapeutic option for alcoholism].
    Soyka M
    Nervenarzt; 2014 May; 85(5):578-82. PubMed ID: 24126432
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nalmefene for elective reversal of procedural sedation in children.
    Chumpa A; Kaplan RL; Burns MM; Shannon MW
    Am J Emerg Med; 2001 Nov; 19(7):545-8. PubMed ID: 11698998
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcome and six month follow up of patients after Ultra Rapid Opiate Detoxification (UROD).
    Albanese AP; Gevirtz C; Oppenheim B; Field JM; Abels I; Eustace JC
    J Addict Dis; 2000; 19(2):11-28. PubMed ID: 10809517
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antagonist treatment of opioid withdrawal translational low dose approach.
    Mannelli P; Gottheil E; Van Bockstaele EJ
    J Addict Dis; 2006; 25(2):1-8. PubMed ID: 16785213
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serious adverse events in the Australian National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD).
    Digiusto E; Shakeshaft A; Ritter A; O'Brien S; Mattick RP;
    Addiction; 2004 Apr; 99(4):450-60. PubMed ID: 15049745
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.
    Fishman M
    Addiction; 2008 Aug; 103(8):1399-401. PubMed ID: 18855831
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Targeted opioid receptor antagonists in the treatment of alcohol use disorders.
    Niciu MJ; Arias AJ
    CNS Drugs; 2013 Oct; 27(10):777-87. PubMed ID: 23881605
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term safety and efficacy of nalmefene in Japanese patients with alcohol dependence.
    Higuchi S; Takahashi M; Murai Y; Tsuneyoshi K; Nakamura I; Meulien D; Miyata H
    Psychiatry Clin Neurosci; 2020 Aug; 74(8):431-438. PubMed ID: 32359104
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low efficacy of non-opioid drugs in opioid withdrawal symptoms.
    Hermann D; Klages E; Welzel H; Mann K; Croissant B
    Addict Biol; 2005 Jun; 10(2):165-9. PubMed ID: 16191669
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Nalmefene: a long-acting opioid antagonist. Clinical applications in emergency medicine.
    Wang DS; Sternbach G; Varon J
    J Emerg Med; 1998; 16(3):471-5. PubMed ID: 9610980
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rapid opioid detoxification during general anesthesia: a review of 20 patients.
    Gold CG; Cullen DJ; Gonzales S; Houtmeyers D; Dwyer MJ
    Anesthesiology; 1999 Dec; 91(6):1639-47. PubMed ID: 10598605
    [TBL] [Abstract][Full Text] [Related]  

  • 57. First case of stress cardiomyopathy as a result of methadone withdrawal secondary to drug-drug interaction.
    Lemesle F; Lemesle F; Nicola W; Pierre Jonville-Béra A
    Am J Emerg Med; 2010 Mar; 28(3):387.e5-6. PubMed ID: 20223408
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Open-label trial of oral nalmefene therapy for the pruritus of cholestasis.
    Bergasa NV; Schmitt JM; Talbot TL; Alling DW; Swain MG; Turner ML; Jenkins JB; Jones EA
    Hepatology; 1998 Mar; 27(3):679-84. PubMed ID: 9500694
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Double-blind, randomized study of nalmefene and naloxone in emergency department patients with suspected narcotic overdose.
    Kaplan JL; Marx JA; Calabro JJ; Gin-Shaw SL; Spiller JD; Spivey WL; Gaddis GM; Zhao N; Harchelroad FP
    Ann Emerg Med; 1999 Jul; 34(1):42-50. PubMed ID: 10381993
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled trial of Oxytrex.
    Chindalore VL; Craven RA; Yu KP; Butera PG; Burns LH; Friedmann N
    J Pain; 2005 Jun; 6(6):392-9. PubMed ID: 15943961
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.